Printer Friendly

ISIS FILES WITH FDA TO BEGIN CLINICAL TRIALS OF ANTISENSE DRUG; FIRST ANTISENSE COMPOUND TO BE INJECTED INTO HUMANS

 ISIS FILES WITH FDA TO BEGIN CLINICAL TRIALS OF ANTISENSE DRUG;
 FIRST ANTISENSE COMPOUND TO BE INJECTED INTO HUMANS
 CARLSBAD, Calif., Jan. 30 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIP), announced today that it has filed an Investigational New Drug (IND) application with the Food and Drug Administration (FDA) for the use of ISIS 2105 for the treatment of genital warts associated with human papillomavirus (HPV). If permission is granted to commence human clinical trials, ISIS 2105 will be the first antisense compound to be injected into humans.
 Antisense drugs bind to messenger RNA molecules that code for disease-causing proteins thereby inhibiting their production. In contrast, a traditional drug inhibits the performance of a single disease-causing protein after its synthesis. As a result, the therapeutic benefit of antisense drugs at this stage in the disease- causing process has the potential to be more pronounced than that of traditional drugs.
 In humans, papillomaviruses cause a variety of diseases, the most prevalent of which is the common wart. The incidence of genital warts is growing rapidly. In 1989, nearly 1.5 million office visits for genital warts were recorded in the United States. HPV infections of the cervix are associated with cervical cancer in infected women and with laryngeal papillomatosis in the newborns of infected mothers. Current treatments for HPV infections are not curative and recurrences are frequent. Surgical interventions, the most common treatment, may cause spreading of the virus and are painful, disfiguring and often unsuccessful.
 Isis believes that ISIS 2105 may be curative and prevent recurrences and spread of genital warts. Further, initial trials will employ intralesional injections to treat HPV, an approach which Isis believes will facilitate early clinical development and regulatory approval.
 Stanley T. Crooke, M.D., Ph.D., Isis' chief executive officer, commented, "Today's filing represents Isis' first IND, an important milestone for our three-year-old company." Crooke added, "As general awareness of the severity of HPV increases, it is important that we seek new ways to treat and cure this important disease."
 Isis Pharmaceuticals, Inc., based in Northern San Diego County, is engaged in the discovery, development and marketing of novel human therapeutic products based on antisense oligonucleotides.
 -0- 1/30/92
 /CONTACT: Daniel L. Kisner, M.D., of Isis, 619-431-2397; or Anthony J. Russo of Noonan/Russo Communications, 212-979-9180, for Isis/
 (ISIP) CO: Isis Pharmaceuticals, Inc. ST: California IN: MTC SU:


GK-TS -- NY010 -- 5172 01/30/92 11:00 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 30, 1992
Words:403
Previous Article:NEW JOINT VENTURE USES JAPANESE TECHNOLOGY TO CREATE AMERICAN JOBS; PLANT DEDICATION HIGHLIGHTS POSITIVE U.S./JAPANESE RELATIONS
Next Article:BIOPHARMACEUTICS PROPOSES EXCHANGE OF $12.3 MILLION IN SHARES TO ACQUIRE AMSWISS SCIENTIFIC
Topics:


Related Articles
ISIS COMPLETES NORMAL SUBJECT STUDY AND INITIATES TRIALS IN PATIENTS WITH ITS FIRST ANTISENSE DRUG
ISIS TEAM DETERMINES THAT ANTISENSE COMPOUNDS MAY BE EFFECTIVE AGAINST CANCER
ISIS PHARMACEUTICALS COMMENCES CLINICAL TRIALS FOR ANTISENSE DRUG TO INHIBIT ICAM-1
ISIS STUDY SHOWS ANTISENSE COMPOUND
ISIS PUBLICATIONS DESCRIBE ADVANCES IN VALIDATING ANTISENSE MECHANISM OF ACTION AND IMPROVING EFFECTIVENESS OF ANTISENSE DRUGS
ISIS INITIATES PHASE I CLINICAL TRIALS FOR A NOVEL ANTISENSE CANCER COMPOUND TO INHIBIT C- RAF KINASE INHIBITION
ISIS AND COLLABORATORS DEMONSTRATE DECREASE IN INFLAMMATORY RESPONSE VIA ICAM-1 INHIBITION IN MOUSE MODEL OF PNEUMONIA
ISIS ANTISENSE COMPOUND DEMONSTRATES POTENT, SELECTIVE ANTI-TUMOR ACTIVITY IN MODELS OF HUMAN CANCER
ISIS ANTICANCER COMPOUND INHIBITS TUMOR GROWTH IN ANIMALS THROUGH ANTISENSE
Isis' novel second-generation antisense drugs continue to show promise Through added safety.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters